INHALAMBDA: Modulating Host Immunity in The Airways With Interferon Lambda Encoding mRNA

Time: 9:30 am
day: Conference Day Two


  • Using Stabilised NanoParticle (SNaP) LNP platform to locally administer the drug to the lungs through inhalation or nasal spray
  • Inducing an innate immune defence response in the mucosa at virus entry sites and inhibiting viral replication through extraordinarily stable lipidoid formulation of mRNDA
  • Presenting preclinical results of antiviral efficacy of mRNA encoded IFN-lambda and Evaluating the safety, tolerability, and target engagement of the candidate in healthy participants for the treatment and prophylaxis of respiratory viral infections